{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.12","upperLimit":"5.98","value":"5.54"},{"groupId":"OG001","lowerLimit":"3.71","upperLimit":"5.55","value":"4.39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Time to CR was defined for participants in the expansion cohorts who had achieved response on study as the time from date of the first dose of study drug to date of the first documentation of response. Time to CR was analyzed using the Kaplan-Meier method.","dispersionType":"Full Range","groups":[{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG000","title":"AML Cohort"},{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG001","title":"MDS Cohort"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all participants who received at least 1 dose of any study treatment.","reportingStatus":"POSTED","timeFrame":"maximum of 23 months in AML cohort and 34 months in MDS cohort","title":"Time to CR in the AML and MDS Cohorts","type":"SECONDARY","unitOfMeasure":"Months"}